1.29
+0.015(+1.18%)
Currency In USD
| Previous Close | 1.27 |
| Open | 1.3 |
| Day High | 1.32 |
| Day Low | 1.28 |
| 52-Week High | 2.2 |
| 52-Week Low | 1.13 |
| Volume | 54,059 |
| Average Volume | 998,316 |
| Market Cap | 63.02M |
| PE | -5.14 |
| EPS | -0.25 |
| Moving Average 50 Days | 1.41 |
| Moving Average 200 Days | 1.37 |
| Change | 0.02 |
If you invested $1000 in MediciNova, Inc. (MNOV) 10 years ago, it would be worth $366.1 as of December 29, 2025 at a share price of $1.285. Whereas If you bought $1000 worth of MediciNova, Inc. (MNOV) shares 5 years ago, it would be worth $251.47 as of December 29, 2025 at a share price of $1.285.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
GlobeNewswire Inc.
Dec 18, 2025 11:00 AM GMT
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successf
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
GlobeNewswire Inc.
Dec 08, 2025 11:00 AM GMT
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the
Message from the CEO to MediciNova Shareholders
GlobeNewswire Inc.
Dec 01, 2025 11:00 PM GMT
Strengthening MN-001’s Scientific Foundation and Clinical OutlookLA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis, I would like to provi